北京金穗科技开发有限责任公司 2021 年度-2024 年度 11 月 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-3 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-12 | | 母公司股东权益变动表 | 13-16 | | 财务报表附注 | 17-98 | 联系电话: +86(010) 6554 2288 信永中和会计师事务所 | 北京市东城区朝阳门北大街 telephone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 9/F. Block A. Fu Hua Ma No 8 Chaovangmen Beida Donachena District Reilin 100027. P.R.China 审计报告 XYZH/2025TYAA2B0011 北京金穗科技开发有限责任公司 中国医药健康产业股份有限公司、中国新兴集团有限责任公 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-034 号 中国医药健康产业股份有限公司 关于召开2025年第二次临时股东大会的通知 2025年第二次临时股东大会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (二)股东大会召集人：董事会 (一)股东大会类型和届次 召开的日期时间：2025 年 5 月 28 日14 点 30 分 召开地点：北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 28 日 至2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网 ...

Core Viewpoint - China National Pharmaceutical Group plans to acquire 100% equity of Jinsui Technology for 302 million yuan, which constitutes a related party transaction [1] Group 1: Acquisition Details - The acquisition will be conducted in cash amounting to 302 million yuan [1] - Jinsui Technology will become a wholly-owned subsidiary of China National Pharmaceutical Group after the transaction [1] - The seller, New Star Group, is a wholly-owned subsidiary of the controlling shareholder, General Technology Group [1] Group 2: Business Operations - Jinsui Technology specializes in e-commerce operation services, covering personal health consumer products and the broader health sector [1] - The company has established partnerships with well-known domestic and international brands such as Philips and Omron [1] - The core business currently focuses on brand authorization and distribution of Philips personal health consumer products [1]

本报讯(记者李乔宇)在全球可持续发展浪潮下，中国医药（600056）健康产业股份有限公司(以下简 称"中国医药")始终秉持"责任治理"与"责任发展"理念，将环境、社会和公司治理(ESG)融入战略核心。 日前，中国医药发布《2024年度环境、社会和公司治理(ESG)报告》，系统披露了其在绿色转型、社会 责任、治理创新等方面的实践与成效。中国医药立足"科、工、贸、技、服"一体化发展的医药及医疗器 械健康产业集团发展目标，坚决扛起企业创新主体责任，彰显了国有医药企业的责任担当与高质量发展 新格局。 中国医药以创新为引擎，完善科研制度，加强人才建设，拥有317名科研人员，研发投入3.46亿元，推 进17个项目立项，不断强化产品管线拓展，完成29个品种申报，获得24个品种批件，为创新发展注入强 劲动能。 中国医药严格遵守国家环保法规，构建完善的环境管理体系，严控污染物排放，环保总投入7063.51万 元，全体系拥有专兼职环保人员115人，11家单位获得环境管理体系认证。公司积极应对气候变化， 2024年万元产值(收入)综合能耗为0.015吨标准煤/万元，二氧化碳排放控制在0.0548吨二氧化碳当量/万 元，圆满完成年度 ...

《2024年度环境、社会和公司治理(ESG)报告》封面 中国医药秉持"人才为本，质量为核"的核心理念，积极履行人文关怀，帮扶困难员工。公司不断完善质量管理体系，强化全员质量意识，中国医药及下属单 位中21家公司通过29项ISO9001、ISO13485质量管理体系认证，以严苛标准铸就品质标杆，持续以优质服务提升客户满意度。在供应链管理层面，中国医药 依托"客商云"及商贸ERP系统，搭建供应商管理数字化平台，以数字技术赋能管理升级，持续完善供应商管理与沟通机制，推动供应链绿色转型，携手供应 商共建阳光、诚信、可持续的供应生态。此外，中国医药投身公益事业，助力乡村振兴，立足专业优势，优选中药材产品，整合地方特色食品、农副产品以 在全球可持续发展浪潮下，中国医药（600056）健康产业股份有限公司(600056.SH)(以下简称"中国医药")始终秉持"责任治理"与"责任发展"理念，将环境、 社会和公司治理(ESG)融入战略核心。2025年4月26日，公司发布《2024年度环境、社会和公司治理(ESG)报告》(以下简称"本报告")，系统披露了其在绿色 转型、社会责任、治理创新等方面的实践与成效。中国医药立足"科、工、 ...

中国医药健康产业股份有限公司 2024 年年度股东大会文件 证券代码：600056 证券简称：中国医药 2024 年年度股东大会 会议资料 2025 年 5 月 16 日 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 中国医药健康产业股份有限公司 2024 年年度股东大会文件 议案目录 | 议案一 | 公司 2024 | 年年度报告全文及摘要 | | 1 | | --- | --- | --- | --- | --- | | 议案二 | 公司 2024 | 年度董事会工作报告 | | 2 | | 议案三 | 公司 2024 | 年度监事会工作报告 | | 14 | | 议案四 | 2024 | 年度独立董事述职报告 | | 19 | | 议案五 | 公司 2024 | 年度财务决算报告 | | 20 | | 议案六 | 关于董事及监事 | 2024 | 年度薪酬情况的议案 | 21 | | 议案七 | 公司 2024 | 年度利润分配方案 | | 22 | | 议案八 | 关于公司 2025 | | 年向银行申请综合授信额度的议案 | 23 | | 议案九 | 关于公司 2025 | | 年度为控 ...

Core Viewpoint - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size expected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and increasing demand for medicines due to aging population and improved healthcare systems [1][11]. Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect medicines, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2]. Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary services. The upstream involves the supply of materials like plastics, glass, metals, and paper, which are crucial for the manufacturing of packaging materials [3]. Industry Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation. The industry has evolved from relying on imports to adopting advanced technologies and focusing on brand building and market expansion [6]. Current Industry Status - China is the world's largest producer of plastic products, with a production volume of 77.08 million tons in 2024. The availability and pricing of plastic products directly impact the pharmaceutical packaging industry [9][11]. Market Structure - The market structure of the pharmaceutical packaging industry is diverse, with plastic packaging holding a 48% share, followed by glass packaging at 28%, metal packaging at 11%, and rubber packaging at 7% [12]. Key Enterprises Analysis - The competitive landscape of the pharmaceutical packaging industry is diverse and intense. Key players include Shandong Pharmaceutical Glass, Zhengchuan Co., Hualan Co., Haishun New Materials, and Huqiang Technology, each with unique strengths and market positions [15][18][20]. Future Development Trends - The industry is moving towards high-end and high-performance packaging materials, focusing on new technologies and innovative designs to meet the demands of high-end pharmaceuticals [22]. - Green and environmentally friendly packaging is becoming a significant trend, with companies seeking biodegradable and recyclable materials to reduce environmental impact [23]. - The industry is also undergoing consolidation and internationalization, with companies optimizing resources and expanding into international markets to enhance competitiveness [24].

Group 1 - The US has announced a 10% "baseline tariff" on all countries and a 125% tariff on China, while other countries are exempt for 90 days [1] - China exports $19.047 billion to the US, accounting for 18% of its total exports, but has a higher reliance on the "Belt and Road" initiative and the EU market [1] - If tariffs are imposed on pharmaceuticals, the burden may fall on Chinese raw material suppliers, especially if downstream clients in Europe and the US face financial difficulties [1] Group 2 - Medical devices have already seen a 20-50% tariff increase, with most companies having inventory that will buffer short-term sales [2] - Low-value consumables will face squeezed profit margins, with an average net profit margin of 13.9% for listed companies in 2024, and additional tariffs of 25-50% expected in early 2025 [2] - Many multinational pharmaceutical and medical device companies have announced plans to invest over $150 billion in the US over the next five years, indicating a long-term shift towards US pharmaceutical manufacturing [2] Group 3 - If drug exemptions are lifted, innovative drugs may focus on overseas rights sales, which have high profit margins and favorable competitive landscapes [2] - High-end medical products are expected to see increased exports to other countries, with overseas gross margins potentially offsetting tariff impacts [2] - Industries less affected by tariffs include pharmaceutical distribution, offline pharmacies, hospitals, and blood products, which primarily rely on domestic demand [2]

Group 1 - The A-share market showed mixed performance with the Shanghai Composite Index down 0.05% and the Shenzhen Component Index also down 0.05%, while the North and Sci-Tech 50 indices saw gains of 1.24% and 0.1% respectively [1] - The AI sector is expected to maintain high investment and growth due to rapid technological iterations, strict external restrictions, and supportive internal policies [1] - The Chinese government emphasizes the importance of AI development, focusing on enhancing technological innovation and high-end industry leadership [1][2] Group 2 - Domestic companies are increasingly focusing on overcoming "bottleneck" areas due to tightening US technology restrictions, with notable revenue growth reported by companies like Cambrian [2] - AI products are gaining market traction, with significant funding rounds and economic advantages over human experts, leading to increased product penetration [2] - The medical sector is experiencing a recovery, with a notable increase in the medical equipment bidding market, driven by domestic substitution and high-end product demand [4] Group 3 - The medical device sector is seeing a normalization of high-value consumables procurement, with policies supporting innovative medical devices expected to enhance their development [5] - The pharmaceutical industry is witnessing a surge in international engagement, with a significant number of Chinese companies participating in global conferences and showcasing new drug research [8] - The recent political bureau meeting highlighted the need for strengthening economic work and supporting technology innovation amidst external shocks [9]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-031 号 中国医药健康产业股份有限公司 关于子公司原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到欧洲药品质量管理局（EDQM） （以下简称"EDQM"）核准签发的曲克芦丁（以下简称"该药品"）《欧洲药典 适用性》证书(以下简称"CEP证书")。现将有关情况公告如下： 一、CEP证书基本信息 化学原料药名称：曲克芦丁（Troxerutin） 证书编号：CEP 2023-419 - Rev 00 证书持有者及生产企业：天方药业有限公司 生产地址：河南省驻马店市驿城区光明路 2 号 发证机构：欧洲药品质量管理局（EDQM） 二、药品其他相关情况 该药品 CEP 证书的获得，标志着公司曲克芦丁产品具备以化学原料药形式进 入欧洲及承认 CEP 证书的其他规范市场的资质，将有助于公司拓展国际化业务及 增强公司产品在全球市场的 ...